Written by
Share article:
Two partnerships between medical imaging AI vendors and companies in the life sciences sector were announced in January 2024. Ultromics entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the detection of cardiac amyloidosis, and Quibim is collaborating with Merck KGaA to develop precision medicine technology targeting a wide range of cancers.
With many AI vendors struggling to generate revenue and access investment in the increasingly competitive funding environment, do these partnerships offer a ray of hope?
Read the full insight with a Signify Premium Insights - Healthcare IT subscription
